Allianz Asset Management
ARRY

Allianz Asset Management’s Array Biopharma Inc ARRY Stock Holding History

Allianz Asset Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-592,903
Closed -$27.5M – 2868
2019
Q2 		$27.5M Buy
592,903
+425,409
+254% +$11.9M 0.03% 658
2019
Q1 		$4.08M Sell
167,494
-3,540
-2% -$73.7K ﹤0.01% 1549
2018
Q4 		$2.42M Sell
171,034
-3,691
-2% -$56K ﹤0.01% 1686
2018
Q3 		$2.66M Sell
174,725
-144,045
-45% -$2.21M ﹤0.01% 1833
2018
Q2 		$5.35M Sell
318,770
-41,245
-11% -$656K 0.01% 1494
2018
Q1 		$5.88M Sell
360,015
-29,970
-8% -$480K 0.01% 1471
2017
Q4 		$4.99M Buy
389,985
+12,985
+3% +$148K ﹤0.01% 1622
2017
Q3 		$4.64M Buy
+377,000
New +$3.5M ﹤0.01% 1655
2014
Q3 		– Sell
-236,277
Closed -$1.08M – 2404
2014
Q2 		$1.08M Sell
236,277
-1,325
-0.6% -$5.48K ﹤0.01% 1374
2014
Q1 		$1.12M Sell
237,602
-14,429
-6% -$72.6K ﹤0.01% 1375
2013
Q4 		$1.26M Sell
252,031
-15,029
-6% -$81.8K ﹤0.01% 1340
2013
Q3 		$1.66M Buy
+267,060
New +$1.59M ﹤0.01% 1238

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Allianz Asset Management's ARRY Position: Q3 2019 in Review

Allianz Asset Management sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 592,903 shares — an estimated $27.5M sold.

Allianz Asset Management first reported a position in ARRY in Q3 2013 and held it in 12 quarters. The position peaked at $27.5M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Allianz Asset Management reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Allianz Asset Management sold 592,903 Array Biopharma Inc shares in Q3 2019, an estimated $27.5M.
  • Allianz Asset Management first reported a position in Array Biopharma Inc in Q3 2013 and held it in 12 quarters.
  • Allianz Asset Management's Array Biopharma Inc position peaked at $27.5M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Allianz Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.